National Consensus on Non-metastatic Castration-Resistant Prostate Cancer: more than just a snapshot.
作者信息
Reis Leonardo Oliveira, Dal Col Luciana Saboya Brito, Sadi Marcus Vinícius
机构信息
UroScience, Universidade Estadual de Campinas - Unicamp, Campinas, SP, Brasil.
Pontifícia Universidade Católica de Campinas - PUC-Campinas, Campinas, SP, Brasil.
出版信息
Int Braz J Urol. 2021 Mar-Apr;47(2):374-377. doi: 10.1590/S1677-5538.IBJU.2020.0249.1.
Abstract
摘要
相似文献
1
National Consensus on Non-metastatic Castration-Resistant Prostate Cancer: more than just a snapshot.非转移性去势抵抗性前列腺癌的国家共识：不止是一张快照。
Int Braz J Urol. 2021 Mar-Apr;47(2):374-377. doi: 10.1590/S1677-5538.IBJU.2020.0249.1.
2
Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities.巴西关于非转移性去势抵抗性前列腺癌诊断和治疗的共识：根据患者合并症，重点关注患者、选择、治疗效果、副作用和医生的看法。
Int Braz J Urol. 2021 Mar-Apr;47(2):359-373. doi: 10.1590/S1677-5538.IBJU.2020.0249.
3
Symptoms and Impacts in Metastatic Castration-Resistant Prostate Cancer: Qualitative Findings from Patient and Physician Interviews.转移性去势抵抗性前列腺癌的症状和影响：来自患者和医生访谈的定性发现。
Patient. 2019 Feb;12(1):57-67. doi: 10.1007/s40271-018-0349-x.
4
[Chinese experts consensus on the treatment of metastatic prostate cancer 2018 edition].《中国转移性前列腺癌治疗专家共识（2018版）》
Zhonghua Wai Ke Za Zhi. 2018 Sep 1;56(9):646-652. doi: 10.3760/cma.j.issn.0529-5815.2018.09.002.
5
AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.转移性去势抵抗性前列腺癌患者全血 RNA 中的 AR-V7 转录本与醋酸阿比特龙的反应相关。
J Urol. 2017 Jan;197(1):135-142. doi: 10.1016/j.juro.2016.06.094. Epub 2016 Jul 17.
6
[Apalutamide for metastatic, castration-sensitive prostate cancer].阿帕鲁胺用于转移性去势敏感型前列腺癌
Urologe A. 2019 Dec;58(12):1496-1497. doi: 10.1007/s00120-019-01071-1.
7
A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.一项关于日本转移性去势抵抗性前列腺癌患者中醋酸阿比特龙序贯多西他赛治疗的多中心回顾性分析。
Jpn J Clin Oncol. 2015 Aug;45(8):774-9. doi: 10.1093/jjco/hyv070. Epub 2015 May 15.
8
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.反驳观点：在有症状的转移性去势抵抗性前列腺癌中，多西他赛和镭-223应首先使用哪一种？镭-223是骨转移为主的有症状转移性去势抵抗性前列腺癌的首选治疗方法。
Clin Adv Hematol Oncol. 2015 May;13(5):293-8.
9
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.卡巴他赛联合考比司他和泼尼松与单独卡巴他赛和泼尼松治疗多西他赛治疗后转移性去势抵抗性前列腺癌患者（AFFINITY）：一项随机、开放标签、国际、3 期临床试验。
Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.
10
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌患者的随机、双盲、安慰剂对照、2 期临床试验。
Lancet Oncol. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4.
引用本文的文献
1
Prostate Cancer: A Journey Through Its History and Recent Developments.前列腺癌：其历史与最新进展之旅
Cancers (Basel). 2025 Jan 9;17(2):194. doi: 10.3390/cancers17020194.
2
Treatment Patterns Among Patients With Advanced Prostate Cancer in Brazil: An Analysis of a Private Healthcare System Database.巴西晚期前列腺癌患者的治疗模式：一项私立医疗保健系统数据库分析
World J Oncol. 2022 Dec;13(6):350-358. doi: 10.14740/wjon1476. Epub 2022 Dec 24.
3
Treatment of complex urethral stenosis in public centers from developing countries in 21st century.21世纪发展中国家公共医疗中心复杂尿道狭窄的治疗
Int Braz J Urol. 2022 Mar-Apr;48(2):367-368. doi: 10.1590/S1677-5538.IBJU.2021.0499.
4
Perception of castration value over cost in the metastatic prostate cancer scenario: a contemporary pharmacoeconomic perspective.转移性前列腺癌情况下对去势价值高于成本的认知：当代药物经济学视角
Int Braz J Urol. 2022 Jan-Feb;48(1):175-179. doi: 10.1590/S1677-5538.IBJU.2021.0258.
本文引用的文献
1
Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities.巴西关于非转移性去势抵抗性前列腺癌诊断和治疗的共识：根据患者合并症，重点关注患者、选择、治疗效果、副作用和医生的看法。
Int Braz J Urol. 2021 Mar-Apr;47(2):359-373. doi: 10.1590/S1677-5538.IBJU.2020.0249.
2
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.阿帕鲁胺、恩扎卢胺和达罗他胺治疗非转移性去势抵抗性前列腺癌：系统评价和网络荟萃分析。
Int J Clin Oncol. 2020 Nov;25(11):1892-1900. doi: 10.1007/s10147-020-01777-9. Epub 2020 Sep 14.
3
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.阿帕鲁胺、达罗他胺和恩扎卢胺治疗去势抵抗性前列腺癌非转移性前列腺癌的疗效比较：系统评价和网络荟萃分析。
Urol Oncol. 2020 Nov;38(11):826-834. doi: 10.1016/j.urolonc.2020.03.022. Epub 2020 Jun 28.
4
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.晚期前列腺癌患者的管理：2019年晚期前列腺癌共识会议报告
Eur Urol. 2020 Apr;77(4):508-547. doi: 10.1016/j.eururo.2020.01.012. Epub 2020 Jan 27.
5
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.前列腺特异性膜抗原配体正电子发射断层扫描在非转移性去势抵抗性前列腺癌男性中的应用。
Clin Cancer Res. 2019 Dec 15;25(24):7448-7454. doi: 10.1158/1078-0432.CCR-19-1050. Epub 2019 Sep 11.
6
Metastasis-free Survival-Progress or Lowering the Bar on Nonmetastatic Prostate Cancer?无转移生存期——进展还是降低非转移性前列腺癌的标准？
Eur Urol. 2018 Nov;74(5):682-683. doi: 10.1016/j.eururo.2018.08.018. Epub 2018 Aug 28.
7
Financial Conflict of Interest and Academic Influence Among Experts Speaking on Behalf of the Pharmaceutical Industry at the US Food and Drug Administration's Oncologic Drugs Advisory Committee Meetings.在美国食品药品监督管理局肿瘤药物咨询委员会会议上代表制药行业发言的专家中的利益冲突与学术影响力
Mayo Clin Proc. 2017 Jul;92(7):1164-1166. doi: 10.1016/j.mayocp.2017.04.014.
8
ARN-509: a novel antiandrogen for prostate cancer treatment.ARN-509：一种用于前列腺癌治疗的新型抗雄激素药物。
Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20.
Zotero 插件